Is Hoechst In Talks To Acquire Marion Merrell Dow?
Speculation was once again running high last week that German chemical and pharmaceutical group Hoechst is in the process of clinching a deal to acquire US pharmaceutical company Marion Merrell Dow.
On October 4, Marion Merrell Dow shares were late opening for trading as speculation peaked about a tie-up with the German company. A spokesperson at MMD told the Marketletter that there had been a "rash of buyers" that morning, but refused to make any further comment about the future of the company.
Hoechst too is maintaining its silence about what it is actually doing to expand in the USA (see also page 3). A spokesperson in Germany said: "we are looking to find some alternative to improve our market position in the USA."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze